UFP Industries: Q1 Earnings Snapshot
GRAND RAPIDS, Mich. — GRAND RAPIDS, Mich. — UFP Industries, Inc. (UFPI) on Monday reported first-quarter earnings of $78.8 million.
The Grand Rapids, Michigan-based company said it had net income of $1.30 per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of $1.59 per share.
The wood and materials provider for the construction industry posted revenue of $1.6 billion in the period.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UFPI at https://www.zacks.com/ap/UFPI
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced enrolling the first child in its Phase 2 clinical trials called INTEGUMENT-INFANT. The trial aims to test the safety and tolerability of an investigational topical treatment, ZORYVE cream 0.05% in infants aged 3 months to less than 24 months with mild to moderate atopic dermatitis. There are currently very few approved topical or systemic therapies for infants with atopic dermatitis. Atopic dermatitis lifelong chronic condition in children that can impact the entire family by significantly disrupting sleep, increasing the risk of skin infections, and leading to developmental and emotional strain for both the child and caregivers, said Patrick Burnett, MD, PhD, FAAD, chief medical officer at Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). A biotechnologist working in a laboratory, examining the effects of a Janus Kinase type 1 inhibitor on plaque psoriasis. This INTEGUMENT-INFANT trial builds on previous positive results from the MUSE study, which also evaluated roflumilast cream 0.05% in infants with atopic dermatitis. ZORYVE cream contains roflumilast, a highly potent and selective phosphodiesterase-4 inhibitor designed for topical use. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a commercial-stage dermatology company focused on developing innovative treatments for immune-mediated skin diseases. It develops targeted topical therapies for major inflammatory skin conditions such as atopic dermatitis and alopecia areata. While we acknowledge the potential of ARQT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Exodus Movement (EXOD) Releases May 2025 Treasury Update
Exodus Movement, Inc. (NYSEAMERICAN:EXOD) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, Exodus Movement, Inc. (NYSEAMERICAN:EXOD) released its treasury and monthly metrics update for May 2025. The company reported 2.2 million Monthly Active Users (MAUs) as of May 31, 2025, with 675,000 Passkey Wallets. The MAUs grew significantly from 1.6 million at the end of Q1 2025. Passkeys Wallets represent a new, innovative wallet onboarding technology that allows users to create wallets quickly and securely without traditional passwords, enhancing user experience and scalability. JP Richardson, CEO Exodus Movement, Inc. (NYSEAMERICAN:EXOD) noted that the MAUs benefitted from promotions aimed at Passkeys Wallets. However, the company does not expect this growth to reoccur in June. In addition, the company processed a total of $486 million in exchange volume during May 2025. Around $69 million or 14% of this volume came from XO Swap partners, indicating strong collaboration and integration within the crypto ecosystem. Exodus Movement, Inc. (NYSEAMERICAN:EXOD) is a fintech company that provides secure and easy-to-use cryptocurrency software solutions for individuals and businesses. The company offers multi-asset, self-custodial wallets that give users full control over their digital assets. It also offers tools like Passkeys Wallet for seamless wallet onboarding and XO Swap for efficient crypto swap aggregation. While we acknowledge the potential of EXOD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
